跳转至内容
Merck
所有图片(1)

主要文件

查看所有文档

L5545

Sigma-Aldrich

Levosimendan

≥98% (HPLC)

别名:

(-)-OR-1259, (R)-Simendan, 2-[2-[4-[(4R)-1,4,5,6-Tetrahydro-4-methyl-6-oxo-3-pyridazinyl]phenyl]hydrazinylidene]-propanedinitrile, OR 1259, R)-((4-(1,4,5,6-Tetrahydro-4-methyl-6-oxo-3-pyridazinyl)phenyl)hydrazono) propanedintrile

登录查看公司和协议定价
所有图片(1)

About This Item

经验公式（希尔记法）:
C14H12N6O
CAS号:
141505-33-1
分子量:
280.28
MDL號碼:
MFCD00867135
分類程式碼代碼:
12352202
PubChem物質ID:
329817628
NACRES:
NA.77

品質等級

100

化驗

≥98% (HPLC)

形狀

powder

光學活性

[α]/D -500 to -650°, c = 0.5 in THF

顏色

yellow

溶解度

DMSO: ≥20 mg/mL

儲存溫度

room temp

SMILES 字串

C[C@@H]1CC(=O)NN=C1c2ccc(N\N=C(\C#N)C#N)cc2

InChI

1S/C14H12N6O/c1-9-6-13(21)19-20-14(9)10-2-4-11(5-3-10)17-18-12(7-15)8-16/h2-5,9,17H,6H2,1H3,(H,19,21)/t9-/m1/s1

InChI 密鑰

WHXMKTBCFHIYNQ-SECBINFHSA-N

基因資訊

human ... PDE3A(5139) , PDE3B(5140) , TNNC1(7134) , TNNI3(7137) , TNNT2(7139)

應用

Levosimendan has been used for screening its anti-human immunodeficiency virus type 1 (HIV-1) property. It has also been used for screening its cytotoxic effects in TP53 mutant and wild-type lung adenocarcinoma cell lines

生化／生理作用

Levosimendan has a potential to inhibit both acute human immunodeficiency virus type 1 (HIV-1) replication and the reactivation of latent HIV-1 proviruses. Therefore, it is considered to be a promising anti-HIV-1 agent.
Levosimendan is a calcium sensitiser.
Levosimendan is a calcium sensitiser. The compound increases the sensitivity of the heart to calcium, thus increasing cardiac contractility without a rise in intracellular calcium. Levosimendan binds to cardiac troponin C in a calcium-dependent manner and stabilizes troponin C. This is followed by actin-myosin cross-bridges, without increasing myocardial consumption of ATP. Additionally the compound acts as vasodilator by opening an ATP-sensitive potassium channels. Levosimendan is a drug used for treatment of congestive heart failure. Also it can be used to treat calcium channel blocker overdose.

象形圖

Exclamation mark
GHS07

訊號詞

Warning

危險聲明

H302 + H312 + H332

危險分類

Acute Tox. 4 Dermal - Acute Tox. 4 Inhalation - Acute Tox. 4 Oral

儲存類別代碼

11 - Combustible Solids

水污染物質分類（WGK）

WGK 3

閃點（°F）

Not applicable

閃點（°C）

Not applicable

历史批次信息供参考:

分析证书(COA)

Lot/Batch Number
125M4709V
114M4750V
114M4709V
052M4707V
121M4714V

没有发现合适的版本？

如果您需要特殊版本，可通过批号或批次号查找具体证书。

搜索COA

已有该产品？

在文件库中查找您最近购买产品的文档。

访问文档库

Annina Jacky et al.
Journal of cardiothoracic and vascular anesthesia, 32(5), 2112-2119 (2018-05-12)
Pharmacodynamics suggests that levosimendan might be a valuable inotrope for weaning from extracorporeal life support (ECLS). As there is a paucity of evidence regarding the effectiveness and safety of such an approach, the aim was to report the authors' experiences
Julia Hasslacher et al.
Critical care (London, England), 15(4), R166-R166 (2011-07-14)
Levosimendan is an extensively investigated inodilator showing also cardioprotective and antiinflammatory effects. The aim of our study was to explore the influence of levosimendan on polymorphonuclear leucocytes (PMN), a main source of reactive oxygen species, in vitro and in patients
Peter Onody et al.
PloS one, 8(9), e73758-e73758 (2013-09-17)
Temporary occlusion of the hepatoduodenal ligament leads to an ischemic-reperfusion (IR) injury in the liver. Levosimendan is a new positive inotropic drug, which induces preconditioning-like adaptive mechanisms due to opening of mitochondrial KATP channels. The aim of this study was
A Candidate Cell-Selective Anticancer Agent
Probe Reports from the NIH Molecular Libraries Program, 146, 76-85 (2014)
Pertti K Suominen
BMC anesthesiology, 11, 18-18 (2011-10-07)
Levosimendan has pharmacologic and hemodynamic advantages over conventional intravenous inotropic agents. It has been used mainly as a rescue drug in the pediatric intensive care unit or in the operating room. We present the largest single-center experience of levosimendan in
查看所有相关文献

我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.

联系技术服务部门